{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:50:55Z","timestamp":1790268655631,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.bioorg.2021.105334","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T03:41:42Z","timestamp":1631072502000},"page":"105334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of VEGFR2"],"prefix":"10.1016","volume":"116","author":[{"given":"Sahar M.","family":"Abou-Seri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal A.M.","family":"Eissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed G.M.","family":"Behery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farghaly A.","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2021.105334_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjc.6601401","article-title":"Angiogenesis inhibitors in clinical development; where are we now and where are we going?","volume":"90","author":"Eskens","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2021.105334_b0010","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1634\/theoncologist.2009-0178","article-title":"FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma","volume":"15","author":"Kwitkowski","year":"2010","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.bioorg.2021.105334_b0015","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12079-016-0352-8","article-title":"VEGF-A\/VEGFR2 signaling network in endothelial cells relevant to angiogenesis","volume":"10","author":"Abhinand","year":"2016","journal-title":"J. Cell Commun. Signal."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105334_b0020","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1021\/jm701129j","article-title":"Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis","volume":"51","author":"La","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105334_b0025","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3390\/pharmaceutics11090477","article-title":"Magnetoliposomes containing calcium ferrite nanoparticles for applications in breast cancer therapy","volume":"11","author":"Pereira","year":"2019","journal-title":"Pharmaceutics."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105334_b0030","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.3109\/14756366.2012.729826","article-title":"Pharmacophore based 3D-QSAR modeling and free energy analysis of VEGFR-2 inhibitors","volume":"28","author":"Rajagopalan","year":"2013","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105334_b0035","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.bioorg.2018.10.071","article-title":"Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity","volume":"82","author":"Elsayed","year":"2019","journal-title":"Bioorg. Chem."},{"issue":"24","key":"10.1016\/j.bioorg.2021.105334_b0040","doi-asserted-by":"crossref","first-page":"10797","DOI":"10.1021\/jm301085w","article-title":"Vascular endothelial growth factor (VEGF) receptors: Drugs and new inhibitors","volume":"55","author":"Musumeci","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105334_b0045","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bioorg.2014.05.010","article-title":"Design, synthesis and biological evaluation of type-II VEGFR-2 inhibitors based on quinoxaline scaffold","volume":"56","author":"Shahin","year":"2014","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.105334_b0050","doi-asserted-by":"crossref","first-page":"24460","DOI":"10.1038\/srep24460","article-title":"Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents","volume":"6","author":"Aziz","year":"2016","journal-title":"Sci. Rep."},{"issue":"18","key":"10.1016\/j.bioorg.2021.105334_b0055","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1016\/S0960-894X(03)00656-5","article-title":"The kinetics of binding to p38 MAP kinase by analogues of BIRB 796","volume":"13","author":"Regan","year":"2003","journal-title":"Bioorganic Med. Chem. Lett."},{"issue":"19","key":"10.1016\/j.bioorg.2021.105334_b0060","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2021.105334_b0065","unstructured":"Mckenna, Application Data (60) Provisional application No, 2004. https:\/\/patents.google.com\/patent\/US20070020704A1\/en (accessed December 23, 2020)."},{"issue":"15","key":"10.1016\/j.bioorg.2021.105334_b0070","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1021\/jm800566m","article-title":"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2- pyrimidinyl]amino]-2-methyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor","volume":"51","author":"Harris","year":"2008","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2021.105334_b0075","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-11-2041","article-title":"Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice","volume":"18","author":"Inoue","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105334_b0080","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1517\/13543784.17.5.741","article-title":"Axitinib for renal cell carcinoma","volume":"17","author":"Sonpavde","year":"2008","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"12","key":"10.1016\/j.bioorg.2021.105334_b0085","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105334_b0090","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jare.2017.06.006","article-title":"Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies \u2013 A review","volume":"8","author":"Al-Abd","year":"2017","journal-title":"J. Adv. Res."},{"issue":"11","key":"10.1016\/j.bioorg.2021.105334_b0095","doi-asserted-by":"crossref","first-page":"14513","DOI":"10.1007\/s13277-016-5364-8","article-title":"Natural products against cancer angiogenesis","volume":"37","author":"Khalid","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.bioorg.2021.105334_b0100","unstructured":"D.B. Mendel, A. Douglas Laird, X. Xin, S.G. Louie, J.G. Christensen, G. Li, R.E. Schreck, T.J. Abrams, T.J. Ngai, L.B. Lee, L.J. Murray, J. Carver, E. Chan, K.G. Moss, J.\u00d6. Haznedar, J. Sukbuntherng, R.A. Blake, L. Sun, C. Tang, T. Miller, S. Shirazian, G. McMahon, J.M. Cherrington, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic\/pharmacodynamic relationship, Clin. Cancer Res. 9 (2003) 327\u2013337. https:\/\/pubmed.ncbi.nlm.nih.gov\/12538485\/ (accessed July 31, 2020)."},{"issue":"9","key":"10.1016\/j.bioorg.2021.105334_b0105","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/13543776.2017.1344215","article-title":"VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012\u20132016)","volume":"27","author":"Peng","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105334_b0110","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1021\/ml400501x","article-title":"Optimization of GPR40 agonists for type 2 diabetes","volume":"5","author":"Liu","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2021.105334_b0115","first-page":"430","article-title":"Synthesis of some new pyrazolines and isoxazoles carrying 4-methylthiophenyl moiety as potential analgesic and antiinflammatory agents, Indian J. Chem. - Sect. B Org","volume":"48","author":"Karabasanagouda","year":"2009","journal-title":"Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105334_b0120","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.pharep.2016.04.017","article-title":"Anti-inflammatory properties of an isoxazole derivative - MZO-2","volume":"68","author":"M\u0105czy\u0144ski","year":"2016","journal-title":"Pharmacol. Reports."},{"key":"10.1016\/j.bioorg.2021.105334_b0125","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1747-0285.2010.00956.x","article-title":"Inhibition of HIV-1 replication by isoxazolidine and isoxazole sulfonamides","volume":"75","author":"Loh","year":"2010","journal-title":"Chem. Biol. Drug Des."},{"issue":"8","key":"10.1016\/j.bioorg.2021.105334_b0130","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1158\/0008-5472.CAN-07-5256","article-title":"NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis","volume":"68","author":"Eccles","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2021.105334_b0135","first-page":"907","article-title":"Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review)","volume":"46","author":"Sol\u00e1rov\u00e1","year":"2015","journal-title":"Int. J. Oncol."},{"issue":"50","key":"10.1016\/j.bioorg.2021.105334_b0140","doi-asserted-by":"crossref","first-page":"41439","DOI":"10.1074\/jbc.M507209200","article-title":"Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation","volume":"280","author":"Shin","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105334_b0145","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.bcp.2007.08.027","article-title":"KRIBB3, a novel microtubule inhibitor, induces mitotic arrest and apoptosis in human cancer cells","volume":"75","author":"Shin","year":"2008","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105334_b0150","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1080\/14756366.2018.1504041","article-title":"Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents","volume":"33","author":"\u00c7al\u0131\u015fkan","year":"2018","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105334_b0155","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1515\/hc-2017-0190","article-title":"Synthesis of 2,3-dicyanopyrazine and ethyl 5-amino-4,6-dicyanobiphenyl-3-carboxylate derivatives from ethyl aroylpyruvates","volume":"24","author":"Moloudi","year":"2018","journal-title":"Heterocycl. Commun."},{"issue":"12","key":"10.1016\/j.bioorg.2021.105334_b0160","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s10593-010-0455-8","article-title":"Cyclization of chalcones to isoxazole and pyrazole derivatives","volume":"45","author":"Voskien\u0117","year":"2009","journal-title":"Chem. Heterocycl. Compd."},{"issue":"7","key":"10.1016\/j.bioorg.2021.105334_b0165","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1007\/s00044-010-9420-4","article-title":"Synthesis, anti-HSV-1, and cytotoxic activities of some new pyrazole- and isoxazole-based heterocycles","volume":"20","author":"Dawood","year":"2011","journal-title":"Med. Chem. Res."},{"issue":"9","key":"10.1016\/j.bioorg.2021.105334_b0170","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1007\/s00044-019-02388-4","article-title":"Novel isoxazole derivatives as potential antiparkinson agents: synthesis, evaluation of monoamine oxidase inhibitory activity and docking studies","volume":"28","author":"Agrawal","year":"2019","journal-title":"Med. Chem. Res."},{"issue":"21","key":"10.1016\/j.bioorg.2021.105334_b0175","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1021\/jo00142a033","article-title":"Reaction of Acyl Azide and Amines. Kinetics and Mechanism","volume":"47","author":"Berndt","year":"1982","journal-title":"J. Org. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2021.105334_b0180","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1055\/s-2008-1067196","article-title":"Iodobenzene dichloride in combination with sodium azide for the effective synthesis of carbamoyl azides from aldehydes","volume":"2008","author":"Li","year":"2008","journal-title":"Synthesis (Stuttg)."},{"key":"10.1016\/j.bioorg.2021.105334_b0185","author":"Techniques","year":"1996","journal-title":"Elsevier"},{"issue":"4","key":"10.1016\/j.bioorg.2021.105334_b0190","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1039\/D0RE00034E","article-title":"Acyl azide generation and amide bond formation in continuous-flow for the synthesis of peptides","volume":"5","author":"Mata","year":"2020","journal-title":"React. Chem. Eng."},{"key":"10.1016\/j.bioorg.2021.105334_b0195","unstructured":"Comprehensive Organic Functional Group Transformations;, 09 (2007). https:\/\/books.google.com.eg\/books?id=cAm7rA_D25wC&pg=PA266&lpg=PA266&dq=Amides+acid+becomes+activated%5C+without+itself+attacking+the+diimide%5B+For+a+primary+amine+at+least%5C+there+is+a+possibility+that+the+amine+could+become+part+of+a+mixed+diimide+%22 (accessed July 31, 2020)."},{"issue":"22","key":"10.1016\/j.bioorg.2021.105334_b0200","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/cmdc.201800518","article-title":"The Curtius Rearrangement: Applications in Modern Drug Discovery and Medicinal Chemistry","volume":"13","author":"Ghosh","year":"2018","journal-title":"ChemMedChem"},{"issue":"12","key":"10.1016\/j.bioorg.2021.105334_b0205","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1039\/C8OB00138C","article-title":"The Curtius rearrangement: Mechanistic insight and recent applications in natural product syntheses","volume":"16","author":"Ghosh","year":"2018","journal-title":"Org. Biomol. Chem."},{"issue":"09","key":"10.1016\/j.bioorg.2021.105334_b0210","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1055\/s-0030-1259964","article-title":"Propylphosphonic anhydride (T3P\u00ae)-mediated one-pot rearrangement of carboxylic acids to carbamates","volume":"2011","author":"Augustine","year":"2011","journal-title":"Synthesis (Stuttg)."},{"key":"10.1016\/j.bioorg.2021.105334_b0215","first-page":"2798","article-title":"Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies","volume":"8","author":"Stopeck","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bioorg.2021.105334_b0220","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ejmech.2004.06.007","article-title":"Synthesis and antimicrobial activities of some new 1-(5-phenylamino-[1,3,4] thiadiazol-2-yl)methyl-5-oxo-[1,2,4]triazole and 1-(4-phenyl-5-thioxo-[1,2,4] triazol-3-yl)methyl-5-oxo- [1,2,4]triazole derivatives","volume":"39","author":"Demirbas","year":"2004","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105334_b0225","first-page":"12","article-title":"Synthesis and conformational assignment of N-(E)- stilbenyloxymethylenecarbonyl-substituted hydrazones of acetone and o-(m-and p-) chloro- (nitro-) benzaldehydes by means of 1H and 13C NMR spectroscopy","volume":"1","author":"Patorski","year":"2013","journal-title":"J. Spectrosc."},{"key":"10.1016\/j.bioorg.2021.105334_b0230","first-page":"1","article-title":"JNCI Journal of the National Cancer Institute Way to Better DNA","volume":"37","author":"Journals","year":"2008","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.bioorg.2021.105334_b0235","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/hep.27236","article-title":"Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma","volume":"60","author":"Peng","year":"2014","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.bioorg.2021.105334_b0240","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1158\/1078-0432.CCR-13-2620","article-title":"Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET","volume":"20","author":"Xiang","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2021.105334_b0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43046-020-0016-x","article-title":"Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview","volume":"32","author":"Rashed","year":"2020","journal-title":"J. Egypt. Natl. Canc. Inst."},{"issue":"1-2","key":"10.1016\/j.bioorg.2021.105334_b0250","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"issue":"12","key":"10.1016\/j.bioorg.2021.105334_b0255","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1470-2045(03)01277-4","article-title":"Anticancer therapy targeting the apoptotic pathway","volume":"4","author":"Hu","year":"2003","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105334_b0260","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1080\/14756366.2018.1564046","article-title":"Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR\/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis","volume":"34","author":"Maher","year":"2019","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105334_b0265","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3329\/bjp.v12i2.30892","article-title":"MTT assay to evaluate the cytotoxic potential of a drug","volume":"12","author":"Bahuguna","year":"2017","journal-title":"Bangladesh J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105334_b0270","doi-asserted-by":"crossref","first-page":"FSO252","DOI":"10.4155\/fsoa-2017-0075","article-title":"Dual inhibitors of hepatitis C virus and hepatocellular carcinoma: design, synthesis and docking studies","volume":"4","author":"El-Miligy","year":"2018","journal-title":"Futur. Sci. OA."},{"key":"10.1016\/j.bioorg.2021.105334_b0275","doi-asserted-by":"crossref","first-page":"102988","DOI":"10.1016\/j.bioorg.2019.102988","article-title":"3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation","volume":"89","author":"Sobhy","year":"2019","journal-title":"Bioorg. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105334_b0280","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/cbdd.13493","article-title":"Exploring binding mechanisms of VEGFR2 with three drugs lenvatinib, sorafenib, and sunitinib by molecular dynamics simulation and free energy calculation","volume":"93","author":"Wang","year":"2019","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2021.105334_b0285","unstructured":"Protein Data Bank, RCSB PDB: Homepage, Rcsb Pdb. (2019) 1. https:\/\/www.rcsb.org\/ (accessed July 31, 2020)."},{"key":"10.1016\/j.bioorg.2021.105334_b0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep42717","article-title":"SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2021.105334_b0295","first-page":"584","article-title":"Feasibility of Drug Screening with Panels of Human Tumor Cell Lines Using a Microculture Tetrazolium Assay","volume":"48","author":"Alley","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2021.105334_b0300","first-page":"622","article-title":"The National Cancer Institute: Cancer drug discovery and development program","volume":"19","author":"Grever","year":"1992","journal-title":"Semin. Oncol."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105334_b0305","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ddr.430340203","article-title":"Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen","volume":"34","author":"Boyd","year":"1995","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2021.105334_b0310","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejmech.2016.09.099","article-title":"Design, synthesis and cytotoxic activity of certain novel chalcone analogous compounds","volume":"126","author":"El-Meligie","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105334_b0315","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1080\/14756366.2018.1503654","article-title":"Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors","volume":"33","author":"AbdElhameid","year":"2018","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2021.105334_b0320","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/iub.1188","article-title":"Caffeic acid phenethyl ester synergistically enhances docetaxel and paclitaxel cytotoxicity in prostate cancer cells","volume":"65","author":"Tolba","year":"2013","journal-title":"IUBMB Life"},{"key":"10.1016\/j.bioorg.2021.105334_b0325","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.ejmech.2017.10.075","article-title":"Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7","volume":"143","author":"Abdelhaleem","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105334_b0330","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/bmc.3370","article-title":"Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors - review of assay methodologies and perspectives","volume":"29","author":"Sharma","year":"2015","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.bioorg.2021.105334_b0335","first-page":"123","article-title":"Clinical advances in the development of novel VEGFR2 inhibitors","volume":"2","author":"Fontanella","year":"2014","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.bioorg.2021.105334_b0340","doi-asserted-by":"crossref","first-page":"111747","DOI":"10.1016\/j.ejmech.2019.111747","article-title":"Anti-hepatitis-C virus activity and QSAR study of certain thiazolidinone and thiazolotriazine derivatives as potential NS5B polymerase inhibitors","volume":"184","author":"Hassan","year":"2019","journal-title":"Eur. J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821007112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821007112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:28:42Z","timestamp":1758616122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206821007112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":68,"alternative-id":["S0045206821007112"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105334","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of VEGFR2","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105334","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105334"}}